De novo design of D-peptide ligands: Application to influenza virus hemagglutinin

J Jarek Juraszek (Johnson and Johnson Innovative Medicine) R Rameshwar U. Kadam (Department of Integrative Structural and Computational Biology, The Scripps Research Institute) D Davide Branduardi (Johnson and Johnson Innovative Medicine) J Jeroen van Ameijde D Divita Garg (Department of Molecular Medicine, The Scripps Research Institute) N Nicolas Dailly (Johnson and Johnson Innovative Medicine) M Mandy Jongeneelen (Johnson and Johnson Innovative Medicine) J Jan Vermond (Johnson and Johnson Innovative Medicine) J Just P. J. Brakenhoff (Johnson and Johnson Innovative Medicine) B Boerries Brandenburg (Johnson and Johnson Innovative Medicine) M Maria J. P. van Dongen (Johnson and Johnson Innovative Medicine) R Ronald Vogels (Johnson and Johnson Innovative Medicine) R Robert H. E. Friesen (Johnson and Johnson Innovative Medicine) I Ian A. Wilson

Abstract

D-peptides hold great promise as therapeutics by alleviating the challenges of metabolic stability and immunogenicity in L-peptides. However, current D-peptide discovery methods are severely limited by specific size, structure, and the chemical synthesizability of their protein targets. Here, we describe a computational method for de novo design of D-peptides that bind to an epitope of interest on the target protein using Rosetta’s hotspot-centric approach. The approach comprises identifying hotspot sidechains in a functional protein–protein interaction and grafting these side chains onto much smaller structured peptide scaffolds of opposite chirality. The approach enables more facile design of D-peptides and its applicability is demonstrated by design of D-peptidic binders of influenza A virus hemagglutinin, resulting in identification of multiple D-peptide lead series. The X-ray structure of one of the leads at 2.38 Å resolution verifies the validity of the approach. This method should be generally applicable to targets with detailed structural information, independent of molecular size, and accelerate development of stable, peptide-based therapeutics.

Article Details

Volume / Issue Vol. 122, Issue 26
Published July 01, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (14)

J

Jarek Juraszek

Johnson and Johnson Innovative Medicine

R

Rameshwar U. Kadam

Department of Integrative Structural and Computational Biology, The Scripps Research Institute

D

Davide Branduardi

Johnson and Johnson Innovative Medicine

J

Jeroen van Ameijde

D

Divita Garg

Department of Molecular Medicine, The Scripps Research Institute

N

Nicolas Dailly

Johnson and Johnson Innovative Medicine

M

Mandy Jongeneelen

Johnson and Johnson Innovative Medicine

J

Jan Vermond

Johnson and Johnson Innovative Medicine

J

Just P. J. Brakenhoff

Johnson and Johnson Innovative Medicine

B

Boerries Brandenburg

Johnson and Johnson Innovative Medicine

M

Maria J. P. van Dongen

Johnson and Johnson Innovative Medicine

R

Ronald Vogels

Johnson and Johnson Innovative Medicine

R

Robert H. E. Friesen

Johnson and Johnson Innovative Medicine

I

Ian A. Wilson